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Background. Elevated blood pressure has been reported among treatment naı¨ve HIV-infected patients. We investigated prevalence
of hypertension and its associated risk factors in a HAART naı¨ve HIV-infected population in Dar es Salaam, Tanzania. Methods.
A cross-sectional analysis was conducted among HAART naı¨ve HIV-infected patients. Hypertension was defined as systolic blood
pressure (SBP) ≥ 140mmHg and/or diastolic blood pressure (DBP) ≥ 90mmHg. Overweight and obesity were defined as body
mass index (BMI) between 25.0–29.9 kg/m2 and ≥30 kg/m2, respectively. We used relative risks to examine factors associated
with hypertension. Results. Prevalence of hypertension was found to be 12.5%. After adjusting for possible confounders, risk
of hypertension was 10% more in male than female patients. Patients aged ≥50 years had more than 2-fold increased risk for
hypertension compared to 30–39-years-old patients. Overweight and obesity were associated with 51% and 94% increased risk
for hypertension compared to normal weight patients. Low CD4+ T-cell count, advanced WHO clinical disease stage, and
history of TB were associated with 10%, 42%, and 14% decreased risk for hypertension. Conclusions. Older age, male gender, and
overweight/obesity were associated with hypertension. Immune suppression and history of TB were associated with lower risk for
hypertension. HIV treatment programs should screen and manage hypertension even in HAART naı¨ve individuals.
1. Introduction
The introduction of Highly Active Antiretroviral Therapy
(HAART) marked a milestone in the prognosis, course of
infection, and quality of life for people living with human
immunodeficiency virus (HIV) in both developed and devel-
oping countries [1, 2]. Cardiovascular diseases (CVDs) are
increasingly observed in HIV-infected people especially in
developed countries where people with HIV/AIDS are living
much longer [3]. In addition to increased patient longevity,
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data indicate that increased incidence of CVDs is also
attributable to HIV infection itself and use of HAART [4, 5].
Generally, the impact of HIV and HAART on hyper-
tension remains controversial. A recent systematic review
with meta-analysis of over 44,000 HIV-infected patients has
shown themean systolic blood pressure and risk of hyperten-
sion to be significantly higher among HAART exposed com-
pared to HAART naı¨ve individuals [6]. Studies conducted in
Europe and US found higher rates of hypertension among
HIV-infected adults on HAART than uninfected adults [7]
with others indicating no difference [8, 9]. However, results
from a multicenter AIDS cohort study of men with blood
pressure measurements between 1984 and 2003 indicated a
significant association between prolonged use of HAART
with systolic hypertension [10].
A systematic review and meta-analysis from sub-Saharan
Africa found lower blood pressure levels amongHIV-infected
than uninfected adults [11]. Another large, population-based
study from South Africa indicated hypertension to be less
common among HIV-infected adults [12]. However, both
studies from Africa lacked data on long-term HAART use.
Hypertension may develop as a result of long-term HAART
use due to weight gain, drug toxicity, and some immune-
related phenomenon. A study conducted in Nigeria reported
no association between HIV infection and HAART status
with hypertension [13]. However, this study had a relatively
small sample size and was of short duration of HAART in the
treated group. Reports from other studies indicate a slightly
higher prevalence of CVD risk factors among HIV-infected
individuals, especially those on HAART [14, 15].
Data from resource-limited settings among non-HIV-
infected people has indicated increasing rates of traditional
risk factors associated with CVD such as hypertension,
diabetes mellitus, and dyslipidemia, primarily as a result of
obesity and urbanization [16–18]. These risk factors con-
tribute to a significant proportion of overall disease burden
in Africa [19, 20]. The prevalences of metabolic syndrome
and hypertension are reported to be increasing in Africa
[18, 21]. Metabolic syndrome is defined as a cluster of several
cardiometabolic risk factors, including abdominal obesity,
hyperglycemia, dyslipidemia, and elevated blood pressure
[22].
In view of existing gap of knowledge and scarcity of data
on the prevalence and correlates of CVD risk factors espe-
cially among HIV-infected population in resource-limited
settings, we conducted this analysis to assess the prevalence
of hypertension and its associated risk factors in a cohort of
HIV-infected, HAART na¨ıve in Dar es Salaam, Tanzania.
2. Methods
2.1. Study Design, Site, and Population. Data for this cross-
sectional analysis were collected at 12 HIV Care and Treat-
ment Clinics (CTCs) affiliated to Management and Devel-
opment for Health (MDH) and supported by President’s
Emergency Plan for AIDS Relief (PEPFAR) in Dar es Salaam,
Tanzania. The MDH-PEPFAR program was established in
2004 and provided infrastructure, laboratory, and technical
support to HIV CTCs, Prevention of Mother to Child
Transmission (PMTCT) clinics, and Tuberculosis facilities in
Dar es Salaam region. Dar es Salaam has a population ofmore
than fourmillion peoplewith anHIVprevalence of 6.9% [23].
This analysis is comprised of patients who had blood pressure
(BP) measurement taken, were ≥15 years of age, and were
nonpregnant at the time of enrolment.
2.2. Blood Pressure Measurement. Blood pressure measure-
ments were taken on arrival to the clinic using a standardized
digital blood pressuremeasuringmachine (ADMedical Inc.).
Three blood pressure readings were taken on the left upper
armwith the participant in a seated position following at least
5 to 10 minutes of rest. The average of the three readings was
used in this analysis.
2.3. Anthropometric Measurement. Body weight and height
were taken following standard procedures. Body weight (to
the nearest 0.5 kg) was taken with the participant in light
clothing using a SECA scale. Height (to the nearest 0.5 cm)
was measured using a stadiometer with participants wearing
no shoes. Body mass index (BMI) was then calculated as
weight in kilograms divided by square of height in meters
(kg/m2). Overweight was defined as BMI between 25.0 and
29.9 kg/m2 and obesity as BMI ≥ 30 kg/m2.
2.4. Clinical and Laboratory Procedures. Clinical care of
all HIV-infected patients at MDH-supported CTCs fol-
lows the Tanzanian National guidelines for management of
HIV patients [24]. Following HIV diagnosis, patients were
enrolled in the CTC clinic and had WHO clinical stage,
CD4+T-cell count, andHAART eligibility status determined.
Eligible patients were subsequently initiated on HAART after
adherence counseling andwere followed up by physicians and
nurses at two weeks after HAART initiation for assessment
and management of any toxicity. They were then assessed
at monthly clinic visits. Patients not yet meeting HAART
initiation criteriawere followed up at 6monthlyHIV care and
monitoring visits.
Blood samples were collected and separated within 6 to 8
hours of specimen collection and stored at −80-degree centi-
grade for four weeks. Batch testing of samples was performed
by a senior technician at Muhimbili University of Health and
Allied Sciences (MUHAS). Daily calibration of instruments
was done following standardized procedures. The MUHAS
laboratory participates in the College of American Patholo-
gists proficiency testing programs where three general chem-
istry panels including lipids and two calibration verification
panels are taken annually. Immunologic assessment with
CD4+ T-cell count was performed using the FACS Calibur
System (Becton Dickinson, San Jose, California, USA).
TB screening was performed to all patients at baseline
using a TB screener form containing five questions:
(i) History of cough for ≥2 weeks
(ii) History of hemoptysis
(iii) History of fever for ≥2 weeks
(iv) Noticeable weight loss for new patients or weight loss
≥ 3.0 kg in a month
(v) Excessive night sweats for ≥2 weeks.
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All patients who were screened positive for TB (had at least
one of the abovementioned symptoms) had a chest radio-
graph and sputum analysis conducted for diagnosis of TB.
2.5. Data Collection andManagement. Physicians and nurses
completed standard forms capturing demographic, clinical,
laboratory, and therapeutic information at baseline and
follow-up visits. Data reviewers were stationed at each clinic
to ensure completeness of data recording by physicians
and nurses. Data collected was then entered into a secure
computerized database using unique patient identifiers. The
database was updated daily by dedicated data entry clerks
trained to use a prospective data collection instrument.
Weekly quality assurance checks were performed by the
data management team to ensure data accuracy. Data col-
lected for this analysis included baseline demographics, age,
weight, height, blood pressure, midupper arm circumference
(MUAC), body mass index (BMI), WHO clinical disease
stage, and history of prior or current TB.
2.6. Outcomes and Definitions. The primary outcome of in-
terest was hypertension, which was defined according to the
guidelines for management of hypertension in HIV.The Joint
National Committee VII (JNC VII) report released in 2003
categorizes blood pressure as follows: normal blood pressure
(systolic (SBP)/diastolic (DBP) < 120/80mmHg); prehyper-
tension (SBP 120–139mmHg or DBP 80–89mmHg); stage 1
hypertension (SBP 140–159mmHg or DBP 90–99mmHg);
and stage 2 hypertension (SBP ≥ 160mmHg or DBP ≥
100mmHg) [25].
2.7. Ethical Approval. Thestudywas approved by institutional
review boards for human research at Harvard TH Chan
School of Public Health and the Research Ethics Review
Committee of the Muhimbili University of Health and
Allied Sciences. Patients were recruited for participation and
enrolled in the MDH-supported CTCs following written
informed consent.
2.8. Statistical Analysis. Sociodemographic and cardiomet-
abolic characteristics of the study population were described
using mean (SD) or percentage. To examine the factors asso-
ciated with hypertension, prevalence ratios (relative risks)
were estimated using Generalized Estimating Equations
(GEE) with the log link function and the binomial variance
[26, 27]. All multivariate analyses were adjusted for age (<30,
30–39, 40–49, and ≥50 years); gender (male/female); district
(Ilala, Kinondoni, and Temeke); calendar year and season of
enrolment; BMI (underweight, normal weight, overweight,
and obesity); CD4+T-cell count (<350, 350–<500, and≥500);
WHO clinical disease stage (I, II, III, and IV); history of TB;
and current TB/HIV coinfected. The median score test was
used to assess the significance of any trends observed and a
Wald test was used for binary variables. Themissing indicator
method was used in the multivariate models [28]. Statistical
analyses were performed with the statistical software package
SAS (release 9.2). All tests were two-sided, and a 𝑝 < 0.05was
considered statistically significant.
Table 1: Sociodemographic and clinical characteristics of the
participants.
Characteristic Mean ± SD or𝑁 (%)
Age (years) 36.6 ± 9.5
Age categories
<30 7760 (22.9)
30–39 14877 (43.9)
40–49 7964 (23.4)
≥50 3317 (9.8)
Gender
Male 11199 (32.8)
Female 22912 (67.2)
BMI (kg/m2) 21.4 ± 4.8
BMI-defined categories
Underweight (BMI < 18.5 kg/m2) 9235 (27.6)
Normal (BMI 18.5–24.9 kg/m2) 18160 (54.4)
Overweight (BMI 25.0–29.9 kg/m2) 4322 (12.9)
Obesity (BMI ≥ 30 kg/m2) 1693 (5.1)
CD4+ cell count (cells/𝜇L)
<350 23050 (75.5)
350–<500 3748 (12.3)
≥500 3720 (12.2)
WHO clinical disease stage
Stage I 4910 (14.9)
Stage II 6228 (18.9)
Stage III 15128 (45.9)
Stage IV 6686 (20.3)
History of TB infection
Yes 7739 (23.3)
No 25539 (76.7)
Current TB/HIV coinfection
Yes 3245 (9.7)
No 30246 (90.3)
BMI: body mass index; BP: blood pressure; CD4+: cluster of differentiation
4; HIV: human immunodeficiency virus; TB: tuberculosis; WHO: World
Health Organization.
3. Results
3.1. Sociodemographic and Clinical Characteristics of the Study
Population. A total of 34,111 nonpregnant, HAART na¨ıve
patients who had blood pressure measurement taken were
included in the analysis. The baseline demographic and
clinical characteristics of the study patients are summarized
in Table 1. The mean age and BMI of the patients were
36.6 ± 9.5 years and 21.4 ± 4.8 kg/m2, respectively, and
women constituted two-thirds of the study participants.
Three-quarters (75.5%) of the participants had CD4+ T-cell
count of less than 350 cells/𝜇L and two-thirds (66.2%) had
a WHO clinical disease stage III or stage IV. Nearly quarter
of the participants (23.3%) had a positive history of TB and
about one-tenth (9.7%) were currently TB/HIV coinfected
receiving anti-TB treatment.
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Table 2: Mean systolic and diastolic blood pressures and prevalence
of hypertension.
Variable Mean ± SD or𝑁 (%)
Systolic blood pressure, SBP (mmHg) 114.1 ± 18.1
Diastolic blood pressure, DBP (mmHg) 73.1 ± 12.9
Blood pressure categories
Normal BP 19859 (58.2)
Prehypertension 9967 (29.2)
Stage 1 hypertension 2668 (7.8)
Stage 2 hypertension 1617 (4.7)
Hypertension
Yes 4285 (12.5)
No 29826 (87.4)
BP: blood pressure; SD: standard deviation.
3.2. Blood Pressure and Prevalence of Hypertension. Results
on blood pressure measurements are summarized in Table 2.
The mean systolic and diastolic blood pressures were 114.1 ±
18.1mmHg and 73.1 ± 12.9mmHg, respectively. More than
half (58.2%) of the patients had their blood pressure mea-
surement within the normal range and more than quarter
(29.2%) had their blood pressure in the prehypertension
range.Theprevalence of hypertension (combined stages 1 and
2 hypertension) found in this study population was 12.5%.
3.3. Sociodemographic and Clinical Characteristics Associated
with Hypertension. The various sociodemographic and clini-
cal factors associatedwith hypertension among study patients
are summarized in Table 3. Older age (≥50 years), male
gender, overweight and obesity, CD4+ T-cell count (≥500
cells/𝜇L), and WHO clinical disease stage I were all signif-
icantly associated with higher prevalence of hypertension.
WHO clinical disease stage IV, history of TB, and being
TB/HIV coinfected were significantly associated with a lower
prevalence of hypertension.
3.4. Relationship between Age, Gender, and Body Mass Index
with Prevalence of Hypertension. Results for univariate and
multivariate analyses for risk factors associated with hyper-
tension are summarized in Table 4. After adjusting for district
(Ilala, Kinondoni, and Temeke), calendar year and season
of enrolment, age (<30, 30–39, 40–49, and ≥50 years),
gender (male/female), BMI (underweight, normal weight,
overweight, and obesity), CD4+ T-cell count (<350, 350–
<500, and ≥500), WHO clinical disease stage (I, II, III, and
IV), history of TB, and current TB/HIV coinfected, patients
aged 40–49 years and those aged ≥50 years had a 43% [ARR
1.43 (95% CI 1.33, 1.53)] and 2-fold [ARR 2.52 (95% CI 1.92,
3.30)] increased risk for hypertension compared to patients
aged 30–39 years. Male patients had 10% [ARR 1.10 (95%
CI 1.04, 1.17)] increased risk of hypertension compared to
female patients. Overweight and obesity were associated with
51% [ARR 1.51 (95% CI 1.40, 1.62)] and 94% [ARR 1.94 (95%
CI 1.78, 2.12)], respectively, increased risk for hypertension
compared to normal weight patients.
Prevalence of hypertension was significantly lower in
patients with immune suppression at baseline. Hypertension
was 10% (ARR 0.90; 95% CI 0.83, 0.98) lower in patients
with CD4+ T-cell count < 350 cells/𝜇L compared to those
with CD4+ T-cell count ≥ 500 cells/𝜇L. Similarly, patients
with advanced WHO clinical disease stage had significantly
lower risk of hypertension. Patients with WHO clinical
disease stages II and III had 12% and 28% decreased risk for
hypertension compared to patientswith stage I disease.WHO
clinical disease stage IV was associated with 42% decreased
risk for hypertension compared to stage I disease.
History of TB was observed to be protective against
hypertension. Patients with history of TB had statistically
significant 14% decreased risk for hypertension compared to
patients with no history of TB. On the contrary, patients who
were current TB/HIV coinfected had a nonsignificant 5%
increased risk for hypertension.
4. Discussion
We report an appreciable prevalence of hypertension in a
cohort of HAART na¨ıve HIV-infected adults in Tanzania.
We found significant associations between older age, male
gender, and overweight/obesity with higher prevalence of
hypertension. Furthermore, the prevalence of hypertension
was inversely associated with level of immune suppression.
This study is one among few published studies examining the
prevalence of hypertension as one of the key risk factors asso-
ciated with CVD in HIV-infected population from resource-
limited settings.
Arterial hypertension is a major CVD risk factor. How-
ever, there are few studies that have analyzed the relationship
between blood pressure andHIV infection [7, 8]. In our study,
we observed a prevalence of hypertension (combined stages
1 and 2) of 12.5%. The prevalence of hypertension observed
in this study is lower than that reported by studies conducted
elsewhere in Africa [13, 29–31]. Although we did not compare
the prevalence of hypertension to patients onHAART, several
studies have reported higher prevalence of hypertension
among HIV-infected patients on HAART [29, 30, 32, 33],
supporting that HAART is associated with hypertension.
Other studies have found no association between HAART
use and hypertension [9, 34]. Ogunmola et al. reported no
significant difference in the prevalence of hypertension,mean
SBP, and mean DBP between HIV-negative, HIV-positive on
HAART, and HIV-positive HAART na¨ıve patients [13].
The variability in the prevalence of hypertension
observed in our study to that reported by other studies may
be explained by several factors, one of them being the cut-off
for defining hypertension. For example, in most of these
studies, their cut-off point was 160/95mmHg compared to
the definition we used (SBP ≥ 140mmHg and/or DBP ≥
90mmHg).Other factors such as differences in age, ethnicity,
and levels of obesity may also explain the variations in the
observed prevalence of hypertension. In our study, inclusion
of HAART naı¨ve patients only may partly explain the
observed low prevalence of hypertension. Further analysis
comparing with patients on HAART is warranted.
Several mechanisms have been proposed to explain the
link between HIV and CVD [31, 35]. HIV infection, chronic
inflammation, hypercoagulability, and platelet activation
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Table 3: Sociodemographic and clinical characteristics associated with hypertension.
Parameter All
𝑁 = 34,111
Normotensive
𝑁 (%)
Hypertensive
𝑁 (%)
𝑝 value
Age (years) <0.001
<30 7760 7131 (91.9%) 629 (8.1%)
30–39 14877 3289 (89.3%) 1588 (10.7%)
40–49 7964 6756 (84.8%) 1208 (15.2%)
≥50 3317 2505 (75.5%) 813 (24.5%)
Gender <0.001
Male 11199 8423 (75.2%) 2776 (24.8%)
Female 22912 21409 (93.4%) 1503 (6.6%)
BMI-defined obesity <0.001
Underweight (BMI < 18.5 kg/m2) 9235 8643 (93.6%) 592 (6.4%)
Normal (BMI 18.5–24.9 kg/m2) 18160 15884 (87.5%) 2276 (12.5%)
Overweight (BMI 25.0–29.9 kg/m2) 4322 3440 (79.6%) 882 (20.4%)
Obesity (BMI ≥ 30 kg/m2) 1693 1228 (72.5%) 465 (27.5%)
CD4+ cell count (cells/𝜇L) <0.001
<350 23050 20414 (88.6%) 2636 (11.4%)
350–<500 3748 3177 (84.8%) 571 (15.2%)
≥500 3720 3120 (83.9%) 600 (16.1%)
WHO clinical disease stage <0.001
Stage I 4910 3982 (81.1%) 928 (18.9%)
Stage II 6228 5234 (84.0%) 994 (16.0%)
Stage III 15128 13392 (88.5%) 1736 (11.5%)
Stage IV 6686 6139 (91.8%) 547 (8.2%)
History of TB <0.001
Yes 7739 6993 (90.4%) 746 (9.6%)
No 25539 22097 (86.5%) 3442 (13.5%)
Current TB/HIV coinfection <0.001
Yes 3245 2940 (90.6%) 305 (9.4%)
No 30246 26345 (87.1%) 3901 (12.9%)
BMI: body mass index; CD4+: cluster of differentiation 4; HIV: human immunodeficiency virus; TB: tuberculosis; WHO: World Health Organization.
mediated by HIV infection itself contribute to endothelial
dysfunction and subsequent increased CVD risk [15, 36]. It
has been proposed that HIV influences endothelial function
via activated monocytes and resultant cytokine secretion and
via a direct effect of the secreted HIV proteins tat and gp120
[37]. Another mechanism involves free radical physiology,
where excess nitric oxide reacts with oxygen radicals to
produce peroxynitrite, which then causes oxidative damage
to the vascular endothelium, and decreased flow mediated
dilation [38]. Use of HAART in patients infected with HIV-
1 has been shown to reduce markers of endothelial function
and coagulation [15, 31, 35].
We observed a significant association between older
age, male gender, and overweight/obesity and increased
risk for hypertension. These findings are in agreement with
other studies conducted among HIV-infected individuals.
In addition to HAART exposure, these studies found male
gender, advancing age, high body mass index, greater waist
circumference, HIV-hepatitis C coinfection, and ethnicity to
be associated with increased risk of developing hypertension
and coronary heart disease (CHD) in HIV-infected patients
[7, 33]. We have also demonstrated increased mortality
among male patients with HIV in one of our publications
[39].
We observed an inverse association between advanced
HIV disease (defined as lowCD4+T-cell count and advanced
WHO clinical disease stage) and risk for hypertension.
Participants with low CD4+ T-cell count < 350 cells/𝜇L
and those with WHO clinical disease stage IV had lower
risk for hypertension. This finding is contrary to results
from other studies which show that low CD4+ T-cell count
is a risk for CVD [40–43]. The proposed mechanism for
association between low immunity and risk of CVD is
that chronic inflammation that accompanies uncontrolled
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Table 4: Univariate and multivariate adjusted demographic, body mass index, and clinical and immunological factors associated with
prevalence of hypertension.
Unadjusted RR
(95% CI) 𝑝 value
Adjusted RR
(95% CI) 𝑝 value
Age group (years) 0.002 <0.001
15–29 0.76 (0.70–0.83) 0.74 (0.67–0.81)
30–39 Reference Reference
40–49 1.42 (1.32–1.52) 1.43 (1.33–1.53)
50 2.30 (2.14–2.49) 2.52 (1.92–3.30)
Gender <0.001 0.002
Female Reference Reference
Male 1.11 (1.05–1.18) 1.10 (1.04–1.17)
BMI-defined obesity 0.003 <0.001
Underweight (BMI < 18.5 kg/m2) 0.51 (0.47–0.56) 0.57 (0.52–0.62)
Normal (BMI 18.5–24.9 kg/m2) Reference Reference
Overweight (BMI 25.0–29.9 kg/m2) 1.63 (1.52–1.74) 1.51 (1.40–1.62)
Obesity (BMI ≥ 30 kg/m2) 2.19 (2.00–2.38) 1.94 (1.78–2.12)
CD4+ cell count (cells/𝜇L) <0.001 0.003
<350 0.49 (0.44–0.54)
350–<500 0.77 (0.72–0.82)
>500 Reference Reference
WHO Clinical disease stage <0.001 <0.001
Stage I Reference Reference
Stage II 0.83 (0.77–0.90) 0.88 (0.81–0.96)
Stage III 0.58 (0.54–0.63) 0.72 (0.66–0.78)
Stage IV 0.42 (0.38–0.47) 0.58 (0.52–0.64)
History of TB <0.001 <0.001
Yes 0.72 (0.66–0.77) 0.86 (0.78–0.94)
No Reference Reference
Current TB/HIV coinfection 0.410 0.420
Yes 1.08 (0.89–1.18) 1.05 (0.92–1.20)
No Reference Reference
BMI: body mass index; CI: confidence interval; HIV: human immune deficiency virus; RR: risk ratio; TB: tuberculosis; WHO: World Health Organization.
The final model for multivariate analyses included district (Ilala, Kinondoni, and Temeke), calendar year and season of enrolment, age (<30, 30–39, 40–49, and
≥50 years), gender (male/female), BMI (underweight, normal weight, overweight, and obesity), CD4+ cell count (<350, 350–<500, and ≥500), WHO clinical
disease stage (I, II, III, and IV), history of TB, and current TB/HIV coinfected. Themedian score test was used to assess the significance of any trends observed
and a Wald test was used for binary variables.
or more advanced HIV disease is associated with elevated
levels of serummarkers of inflammation and increased levels
of activated CD4+ T-cells and proinflammatory cytokines
that destabilize atherosclerotic plaques leading to CVD event
[42, 44].
Participants with history of TB had a 10% decreased risk
for hypertension, but this protective effect was not observed
among those who were currently TB/HIV coinfected. Few
studies have explored the association between TB and CVD
risk and have reported contradicting conclusions. An age and
sex matched study conducted by Giral et al. [45] showed
that past TB was not associated with a higher prevalence of
atherosclerotic lesions in patients with hypercholesterolemia
patients, while Wu et al. [46] reported that non-CNS TB
does not increase the risk of subsequent ischemic stroke. In
contrary, Sheu et al. [47] found patients with a diagnosis
of TB to be at an increased risk for ischemic stroke. Our
finding of history of TB conferring protective effect against
hypertension further increases the need for further research
to investigate the relationship between TB and CVD and its
risk factors.
While themajor strength of this analysis is its large sample
size, it has several limitations worth mentioning. First, the
cross-sectional design of the study does not provide proof
of causal association between HIV, immune suppression, and
the development of hypertension. Secondly, the analysis was
limited to hypertension and obesity. We did not evaluate
the contribution of other conversional risk factors such as
diabetes, lipid profile, smoking, alcohol drinking, physical
activity, dietary, and other lifestyle related factors. Third,
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inclusion ofHAARTna¨ıve only in the analysismade it impos-
sible to make comparisons with counterpart HIV-infected
patients on HAART or HIV-negative as in other studies
[13, 30]. Fourth, selection bias might have been introduced
by inclusion of patients who attendedMDH-supportedCTCs
only, thus affecting generalizability of the findings. However,
MDH-supported CTCs are publicly accessible and patients
attending these clinicsmay be similar to those attending other
public health facilities CTCs in Dar es Salaam. Despite the
abovementioned limitations, this study remains an important
analysis of blood pressure and its associated risk factors in
a large cohort of HIV-infected HAART na¨ıve patients from
resource-limited settings.
In conclusion, we observed that older age, male gen-
der, and BMI-defined overweight/obesity were significantly
associated with higher prevalence of hypertension even after
adjusting for potential confounders. Furthermore, immune
suppression (defined by lowCD4+T-cell count and advanced
WHO clinical diseased stage) and history of TB were asso-
ciated with decreased risk for hypertension. Screening and
regular monitoring for complications associated with use of
HAART among HIV-infected people have been a routine
clinical practice. HIV treatment programs are recommended
to conduct routine screening and monitoring for hyperten-
sion and other CVD risk factors even prior to initiation
of HAART especially among healthy-looking individuals.
Traditional hypertension control measures such as physical
exercise, weight control, and healthy diet should be rec-
ommended to HIV-infected individuals. Further research is
warranted to investigate the association betweenTB, immune
suppression, and CVD risk observed in this study.
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